You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(6185.HK)跌超4% 澄清新冠疫苗Ad5-nCoV的III期臨牀試驗尚未入組
格隆匯 08-18 13:14
格隆匯8月18日丨因新冠疫苗(Ad5-nCoV)專利申請被授予專利權,康希諾(6185.HK)昨日收漲13.9%,今早該股曾再度高開近4%,但開盤後出現跳水走勢。公司午間發佈澄清公告稱:“重組新型冠狀病毒疫苗Ad5-nCoV的II期臨牀試驗已完成。本公司目前正在與多個國家聯繫,計劃儘快推動Ad5-nCoV國際多中心III期臨牀試驗。截至本公告日,Ad5-nCoV的III期臨牀試驗尚未入組。”康希諾(6185.HK)午後再度出現跳水走勢,現跌4.19%報210.4港元,暫成交2.17億港元,最新總市值763億港元。A股臨近午盤收盤前一度直線拉昇由跌轉升,目前漲超3%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account